A randomised controlled trial comparing standard chemotherapy followed by resection versus ECX chemotherapy followed by resection in patients with resectable adenocarcinoma of the oesophagus
Which treatments work best before surgery for oesophageal cancer?
What is this study about?
Cancer of the oesophagus causes over 7000 deaths in the UK each year and the incidence of this cancer is increasing. This trial is open to people who have been diagnosed with a cancer of the oesophagus (the tube leading from the throat to the stomach) which can be removed by surgery. This cancer is called an adenocarcinoma. Research has shown that patients who are treated with a combination of chemotherapy drugs before their surgery have a better chance of survival than patients who just have surgery. The aim of this trial is to find out if the chemotherapy treatment can be improved to further increase the chances of survival and reduce the side effects associated with the chemotherapy. We are comparing the standard treatment cisplatin and 5-Fluorouracil and surgery, with a newer chemotherapy regimen of eprubicin, cisplatin and capecitabine and surgery.
Type of study
Who is funding the study?
The trial is being funded by the charity Cancer Research UK.
When is it taking place?
Recruitment closed on 31 October 2011. Follow-up will continue until approximately the end of 2015.
Where is it taking place?
Hospitals throughout the UK.
Who is included?
People with operable cancer of the oesophagus.